Cambridge Isotope Laboratories, Inc.
TEWKSBURY, MA / ACCESSWIRE / May 27, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the release of highly enriched 12C methane with low nitrogen content called 12C Methane QG Diamond™ for quantum applications in the field of color and nitrogen vacancy CVD diamonds. 12C Methane QG Diamond will be useful for academics focused on quantum research, those developing diamonds with specific color properties or nitrogen-vacancy (NV) centers, and producers of industrial diamonds. The process of such applications begins with 12C-enriched methane.
"The creation of NV diamonds necessitates an exceptionally high concentration of 12C; minimal and controlled amounts of nitrogen," explains Joel Louette, who oversees business development for Emerging Markets at CIL. "Our interactions with clients from both academia and industry lead us to understand that the ideal material would possess a 12C enrichment of no less than 99.99% and contain nitrogen at levels below 1 part per million."
For over four decades, CIL has honed its skill in separating 13C isotopes through the process of cryogenic distillation. In doing so, CIL has consistently increased its 13C production capabilities to satisfy growing market needs, thereby reinforcing its position as a leader in this sector. Utilizing this deep-seated knowledge in cryogenic distillation, CIL has successfully developed a new 12C separation system, achieving the transition from design to operation in under three years.
Quantum magnetometers based on NV are revolutionizing inertial navigation, enhancing electric vehicle battery efficiency, healthcare, internet security, and may one day enable brain-to-machine interfaces.
About Cambridge Isotope Laboratories, Inc.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.
Cambridge Isotope Laboratories, Inc.
Phone: 1.978.749.8000
Fax: 1.978.749.2768
Contact Information
Crissy Krisko
crissyk@isotope.com
1.978.269.1930
SOURCE: Cambridge Isotope Laboratories, Inc.
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
OmniGuide Holdings26.7.2024 14:07:40 CEST | Press release
OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology
SpeedSize26.7.2024 12:31:59 CEST | Press release
SpeedSize Implements AI-Powered Media Optimization to Deliver Fast and Engaging Online Experience for Never Fully Dressed
Representing Animals Foundation25.7.2024 20:02:26 CEST | Press release
British Veterinary Association Ends Opposition to Vegan Diets for Dogs
U.S. Polo Assn.25.7.2024 13:02:58 CEST | Press release
U.S. Polo Assn. Serves as Official Apparel Partner for 2024 Cowdray Gold Cup
CGFNS International23.7.2024 18:23:16 CEST | Press release
CGFNS International Joins WHO Stakeholder Network to Advance Rehabilitation Care
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom